First European inhalable therapy for group 3 pulmonary hypertension combining a novel drug with novel technique
| Reference number | |
| Coordinator | Attgeno AB |
| Funding from Vinnova | SEK 2 379 999 |
| Project duration | June 2023 - March 2026 |
| Status | Completed |
| Venture | Joint R&D projects for small and medium-sized enterprises in Sweden-Germany |
| Call | German-Swedish Call for joint R&D projects by Small and Medium-sized Enterprises spring 2022 |
Important results from the project
The overall objective of the project was achieved by demonstrating that PDNO (Supernitro) can be administered by inhalation and produce biological effects in the pulmonary circulation. The project also resulted in new analytical methods, improved knowledge of inhalation drug delivery, and a novel technology platform based on nanoporous silicon filters. The results provide an important foundation for the continued development of PDNO and other chemically sensitive drugs for inhalation.
Expected long term effects
The project is expected to make an important contribution to the continued development of PDNO and other chemically sensitive drugs for inhalation through a novel technology platform based on nanoporous silicon filters. The results are also expected to support future research and innovation, the development of new therapies for lung and respiratory diseases, and further advances in inhalation-based drug delivery technologies.
Approach and implementation
The project was carried out through collaboration between Attgeno, Surflay and Örebro University. Activities included development of PDNO manufacturing and analytical methods, inhalation technology, and experimental animal studies. The project progressed largely as planned but was adapted based on the experience and results obtained. Technical challenges and limited access to animal research facilities affected the timeline, but the collaboration enabled the project objectives to be achieved.